Rate of change in early Huntington's disease: A clinicometric analysis

Movement Disorders

Volumn 27, Issue 1, 2012, Pages 118-124

  Meyer, Christina ^a   Landwehrmeyer, Bernhard ^a   Schwenke, Carsten ^b   Doble, Adam ^c   Orth, Michael ^a   Ludolph, Albert C ^a  

^a UNIVERSITY OF ULM   (Germany)

^b SCO:SSiS   (Germany)

^c Foxymed   (France)

Author keywords

Clinical course; Clinical trial; Huntington's disease; Progression; UHDRS

Indexed keywords

ADULT; AGED; ARTICLE; BEHAVIOR; BODY POSTURE; COGNITION; CORRELATION COEFFICIENT; DISEASE COURSE; FEMALE; FINGER; FUNCTIONAL ASSESSMENT; GAIT; HUMAN; HUNTINGTON CHOREA; LONGITUDINAL STUDY; MALE; MOTOR PERFORMANCE; PRIORITY JOURNAL; RATING SCALE; TONGUE DISEASE; UHDRS SCORE;

ADULT; AGED; BEHAVIORAL SYMPTOMS; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; HUMANS; HUNTINGTON DISEASE; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SEVERITY OF ILLNESS INDEX;

EID: 84855933251     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23847     Document Type: Article

References (15)

1. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11: 136- 142.
2. Klempír J, Klempírova O, Spacková N, Zidovská J, Roth J. Unified Huntington's disease rating scale: clinical practice and a critical approach. Funct Neurol 2006; 21: 217-221.
3. Puri BK, Leavitt BR, Hayden MR, et al. Ethyl-EPA in Huntington's disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005; 65: 286-292.
4. van Vugt JP, Siesling S, Vergeer M, van der Velde EA, Roos RA. Clozapine versus placebo in Huntington's disease: a double-blind, randomised, comparative study. Neurol Neurosurg Psychiatry 1997; 63: 35-39.
5. van Vugt JP, Siesling S, Piet KK, et al. Quantitative assessment of daytime motor activity provides a responsive measure of functional decline in patients with Huntington's disease. Mov Disord 2001; 16: 481-488.
6. Landwehrmeyer GB, Dubois B, de Yebenes JG, et al. Riluzole in Huntington's disease: a 3-year, randomized, controlled study. Ann Neurol 2007; 62: 262-272.
7. Chu TM, Weir B, Wolfinger R. A systematic statistical linear modeling approach to oligonucleotide array experiments. Math Biosci 2002; 176: 35-51.
8. Shoulson I, Fahn S, Huntington disease: clinical care and evaluation. Neurology 1979; 29: 1-3.
9. Craufurd D, Thompson JC, Snowden JS. Behavioral changes in Huntington's disease. Neuropsychiatry Neuropsychol Behav Neurol 2001; 14: 219-226.
10. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology 2000; 54: 452-458.
11. Feigin A, Kieburtz K, Bordwell K, et al. Functional decline in Huntington's disease. Mov Disord 1995; 10: 211-214.
12. Mayeux R, Stern Y, Herman A, Greenbaum L, Fahn S. Correlates of early disability in Huntington's disease. Ann Neurol 1986; 20: 727-731.
13. Myers RH, Sax DS, Koroshetz WJ, et al. Factors associated with slow progression in Huntington's disease. Arch Neurol 1991; 48: 800-804.
14. Siesling S, van Vugt JP, Zwinderman KA, Kieburtz K, Roos RA. Unified Huntington's disease rating scale: a follow up. Mov Disord 1998; 13: 915-919.
15. Penney JB, Jr., Young AB, Shoulson I, et al. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptmatic individuals. Mov Disord 1990; 5: 93-99.